Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.

The trailing-twelve-month return on equity at Adamas Pharmaceuticals (NASDAQ: ADMS) is 333.80%. Adamas Pharma's revenue for the same period is $71.10 million.

The trailing-twelve-month return on equity at Versartis (NASDAQ: VSAR) is 142.80%. Versartis' current ratio is 3.60.

The trailing-twelve-month return on equity at NephroGenex (NASDAQ: NRX) is 113.30%. NephroGenex's market capitalization is $50.18 million.

The trailing-twelve-month return on equity at Aquinox Pharmaceuticals (NASDAQ: AQXP) is 60.90%. Aquinox Pharma's EPS for the same period is -$1.57.